CMV-related complications in patients 1 through 17 and in a cohort of 91 patients grouped according to the CMV status of the donor and the type of graft received
. | . | CMV-related complications . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|
. | Tetramers . | Absent . | Reactivation . | Syndrome . | Disease . | |||
| Donor CMV+ T-cell replete | ||||||||
| Patient 1 | Pos | Yes | – | – | – | |||
| Patient 2 | Pos | – | Yes | – | – | |||
| Cohort, n = 39 | ND | 15 | 19 | 5 | 0 | |||
| Donor CMV+ T-cell depleted | ||||||||
| Patient 3 | Pos | – | Yes | – | – | |||
| Patient 4 | Pos | – | Yes | – | – | |||
| Patient 5 | Pos | Yes | – | – | – | |||
| Patient 6 | Pos | – | Yes | – | – | |||
| Patient 7 | Pos | Yes | – | – | – | |||
| Patient 8 | Pos | Yes | – | – | – | |||
| Patient 9 | Pos | Yes | – | – | – | |||
| Patient 10 | Pos | – | Yes | – | – | |||
| Cohort, n = 29 | ND | 21 | 6 | 1 | 1 | |||
| Donor CMV– T-cell replete | ||||||||
| Patient 11 | Neg | – | – | Yes | – | |||
| Patient 12 | Neg | – | – | – | Yes | |||
| Patient 13 | Pos | – | – | – | Yes | |||
| Patient 14 | Neg | Yes | – | – | – | |||
| Patient 15 | Neg | – | Yes | – | – | |||
| Cohort, n = 16 | ND | 3 | 5 | 4 | 4 | |||
| Donor CMV– T-cell depleted | ||||||||
| Patient 16 | Pos | Yes | – | – | – | |||
| Patient 17 | Pos | Yes | – | – | – | |||
| Cohort, n = 7 | ND | 4 | 3 | 0 | 0 | |||
. | . | CMV-related complications . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|
. | Tetramers . | Absent . | Reactivation . | Syndrome . | Disease . | |||
| Donor CMV+ T-cell replete | ||||||||
| Patient 1 | Pos | Yes | – | – | – | |||
| Patient 2 | Pos | – | Yes | – | – | |||
| Cohort, n = 39 | ND | 15 | 19 | 5 | 0 | |||
| Donor CMV+ T-cell depleted | ||||||||
| Patient 3 | Pos | – | Yes | – | – | |||
| Patient 4 | Pos | – | Yes | – | – | |||
| Patient 5 | Pos | Yes | – | – | – | |||
| Patient 6 | Pos | – | Yes | – | – | |||
| Patient 7 | Pos | Yes | – | – | – | |||
| Patient 8 | Pos | Yes | – | – | – | |||
| Patient 9 | Pos | Yes | – | – | – | |||
| Patient 10 | Pos | – | Yes | – | – | |||
| Cohort, n = 29 | ND | 21 | 6 | 1 | 1 | |||
| Donor CMV– T-cell replete | ||||||||
| Patient 11 | Neg | – | – | Yes | – | |||
| Patient 12 | Neg | – | – | – | Yes | |||
| Patient 13 | Pos | – | – | – | Yes | |||
| Patient 14 | Neg | Yes | – | – | – | |||
| Patient 15 | Neg | – | Yes | – | – | |||
| Cohort, n = 16 | ND | 3 | 5 | 4 | 4 | |||
| Donor CMV– T-cell depleted | ||||||||
| Patient 16 | Pos | Yes | – | – | – | |||
| Patient 17 | Pos | Yes | – | – | – | |||
| Cohort, n = 7 | ND | 4 | 3 | 0 | 0 | |||
Pos and Neg indicate the presence or absence, respectively, of tetramer-positive cells approximately 3 months after HSCT; and ND, not done.